Haemonetics Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>HA</div>
HAE -- USA Stock  

USD 113.73  0.93  0.82%

Today we will digest Haemonetics. We will analyze why Haemonetics investors may still consider a stake in the business. In this post, I will also go over a few different drivers affecting Haemonetics' products and services, and explain how it may impact Haemonetics shareholders.
Published over three weeks ago
View all stories for Haemonetics | View All Stories
Here is why Haemonetics (NYSE:HAE) can still attract shareholders
This firm's average rating is Buy from 6 analysts. Macroaxis provides investment recommendation on Haemonetics to complement and cross-verify current analyst consensus on Haemonetics. Our trade recommendations engine determines the entity's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon.

How important is Haemonetics's Liquidity

Haemonetics financial leverage refers to using borrowed capital as a funding source to finance Haemonetics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Haemonetics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Haemonetics's total debt and its cash.

How Haemonetics utilizes its cash?

To perform a cash flow analysis of Haemonetics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Haemonetics is receiving and how much cash it distributes out in a given period. The Haemonetics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Haemonetics Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at 158.22 Million

What did Haemonetics file with SEC?

The SEC filings are financial statements or other formal documents of Haemonetics that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database. Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Haemonetics shareholders may or may not be submitted as SEC does not always require it.
Unclassified Corporate Event
View
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
Regulation FD Disclosure
View
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Haemonetics shareholders may or may not be submitted as SEC does not always require it.

A Deeper look at Haemonetics

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Haemonetics has an asset utilization ratio of 71.68 percent. This indicates that the company is making $0.72 for each dollar of assets. An increasing asset utilization means that Haemonetics is more efficient with each dollar of assets it utilizes for everyday operations.

Will price continue to surge in December 2020?

Latest Information Ratio is up to 0.08. Price may dip again. Haemonetics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Haemonetics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Haemonetics future alpha.

Our Conclusion on Haemonetics

Although some firms within the medical instruments & supplies industry are still a little expensive, even after the recent corrections, Haemonetics may offer a potential longer-term growth to shareholders. While some shorter-term oriented shareholders may not share our view, we believe it may be a good time to take over new shares of Haemonetics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Haemonetics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com